

Publications

The majority of my work is confidential and cannot be shared. However, I have a lot of experience in scientific publishing and have worked on many abstracts, posters and manuscripts across a broad range of therapy areas. I have listed below some publications where I am acknowledged as providing medical writing support or that I have authored.

Addiction Medicine

Alho H, et al. Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. *Int J Drug Policy* 2020; 76:102616.

Kakko J, et al. Craving in opioid use disorder: From neurobiology to clinical practice. *Front Psychiatry* 2019; 10:592.

Autoimmune Disease

Day K, et al. Addressing educational gaps through multidisciplinary team education in eosinophilic oesophagitis management. *J CME* 2023; 12:223033.

Tanaka Y, et al. The management of women of child-bearing age with rheumatoid arthritis: an expert report. *Expert Rev Clin Immunol* 2023; 19:655-669.

Changing the way babies eat: Supporting early allergen feeding around the world. *EMJ* 2022; 7:33-41.

Sabet A, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. *Rheumatol Ther* 2022; 9:693-704.

Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. *Therap Adv Gastroenterol* 2021; 14:17562848211059954.

Taylor PC, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. *J Clin Med* 2021; 10(3):509.

Hercogová J, et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. *Br J Dermatol* 2020; 182:316-26.

Edwards C, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. *Clin Rheumatol* 2019; 38:3381-3390.

Hercogová J, et al. Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the proposed biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-week, phase III study in moderate-to-severe plaque-type psoriasis patients. Presented at the American Academy of Dermatology Annual Meeting 2019.

Baumgart DC, et al. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? *Front Pharmacol* 2019; 10:279.

Edwards CJ, et al. Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. *Expert Opin Biol Ther* 2019; 19:1001-14.

Cardiology

Umemura I, et al. Relationship between left ventricular ejection fraction and treatment characteristics in hospitalized patients with heart failure – A Japanese database analysis. *Circ Rep* 2023; 5(10):392-402.

Suzuki S, et al. Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry. *PLoS ONE* 2023; 18(2):e0280753.

Klein H and Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. *J Med Econ* 2017; 20:640-45.

Diabetes

Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol* 2024; Online ahead of print.

Okemah J, et al. Impact on knowledge, competence and performance of a faculty-led web-based educational activity for type 2 diabetes and obesity: Questionnaire study among health care professionals and analysis of anonymized patient records. *JMIR Form Res* 2023; 7:e49115.

Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asian population with overweight or obesity in the STEP 7 randomised clinical trial. Presented at the 30th European Congress on Obesity, 17-20 May 2023.

Harris SB, et al. The educational impact of online, faculty-led continuing medical education programs in type 2 diabetes: An analysis of changes in the knowledge, competence, and performance of healthcare professionals. *JMIR Med Educ* 2022; 8(4):e40520.

Nguyen-Thi H-Y, et al. Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE trial in Vietnam. *Front Public Health* 2020; 8:56203.

Diagnosics

Kirste I, et al. Quantifying the vaccine-induced humoral immune response to spike-receptor binding domain as a surrogate for neutralization testing following mRNA-1273 (Spikevax) vaccination against COVID-19. *Infect Dis Ther* 2023; 12:177-191.

Taffertshofer K, et al. Design and performance characteristics of the Elecsys Anti-SARS-CoV-2 S assay. *Front Immunol* 2022; 13:1002576.

Hinchliffe E, Carter S, et al. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2013; 15:913-914.

Carter S, et al. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. *Ann Clin Biochem* 2012; 49:570-9

Haemophilia

Realising the Promise of Gene Therapy for Haemophilia: Current Status and Future Innovations. *EMJ* 2023; 11[1]:2-11.

Gene therapy in haemophilia: Updates from clinical trials and insights to future technologies. *EMJ* 2022; 10[5]:2-12.

Klamroth R, et al. Illustrative cases from the pathfinder clinical trials of patients with hemophilia A treated with turoctocog alfa pegol (N8-GP). *Pat Pref Adher* 2021; 15: 2443-54.

Infectious Diseases

Bosheva M, et al. A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. *Pediatr Infect Dis* 2021; 40:e222-9.

Overcash JS, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a Phase 3, randomized, double-blind trial (TARGET). *Clin Infect Dis* 2021; 73:e1507-17.

Welte T, et al. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. *Future Microbiol* 2021; 16:543-555.

Hamed K, et al. Ceftobiprole versus daptomycin in *Staphylococcus aureus* bacteremia: a novel protocol for a double-blind, Phase III trial. *Future Microbiol* 2020; 15:35-48.

Hamed K, et al. No evidence for ceftobiprole-induced immune hemolytic anemia in three Phase 3 clinical trials. *Infect Drug Resist* 2020; 13:3461.

Stemler J, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. *Mycoses* 2020; 63:1060-68.

Oncology

Xia L, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. *Int J Gynecologic Cancer* 2023; 33(12):1861-8.

Muley T, et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. *Tumor Biology* 2023. Online ahead of print.

Xu Y, et al. Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer. An open-label, single-arm, multicentre study. *Lung Cancer* 2023; 183:107288.

Management of thrombosis in high-risk patients: Focus on cancer-associated thrombosis. *EMJ* 2022; 7[3]:30-39.

Gibbs H, Klok FA. New developments, data, and guideline updates: Direct oral anticoagulants for the treatment of venous thromboembolism associated with cancer - interviews with key opinion leaders. *EMJ* 2022; 10(Suppl 3):2-8.

Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. *EMBO J* 2011; 30:4921-30.

Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. *Cell Cycle* 2011; 10:3176-88.

Carter S and Vousden KH. Modifications of p53: competing for the lysines. *Curr Opin Genet Dev* 2009; 19:18-24.

Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. *Cell Cycle* 2008; 7:2519-28.

Carter S and Vousden KH. A role for Numb in p53 stabilization. *Genome Biol* 2008; 9:221.

Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. *Nature Cell Biol* 2007; 9:428-35.

Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. *J Biol Chem* 2004; 279:52835-9.

Hammond DE, Carter S, et al. Met receptor dynamics and signalling. *Curr Top Microbiol Immunol* 2004; 286:21-44.

Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. *Mol Biol Cell* 2003; 14: 1346-54.

Other

Zhou J, et al. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. *J Headache Pain* 2023; 24:103.

Abukhaled M, et al. Case report: Aromatic L-amino acid decarboxylase deficiency in three patients cases from the Kingdom of Saudi Arabia. *Eur J Pediatr* 2023; 182:2535-2545.

Abukhaled M, et al. Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review. *Front Pediatr* 2023; 10:1016239.

Chin KM, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. *Circulation* 2019; 139:2440-50.

Torbicki A, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases. *Circ Cardiovasc Qual Outcomes* 2019; 12:e005095.

Berger RMF, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. *Br J Clin Pharmacol* 2017; 83:1734-44.